OraSure Technologies (NASDAQ:OSUR) Rating Increased to Buy at BidaskClub

Share on StockTwits

OraSure Technologies (NASDAQ:OSUR) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, BidAskClub reports.

Several other equities analysts have also recently weighed in on the company. Zacks Investment Research cut OraSure Technologies from a “hold” rating to a “sell” rating in a research note on Tuesday, July 9th. Canaccord Genuity restated a “hold” rating and set a $7.00 price objective on shares of OraSure Technologies in a research note on Wednesday, August 14th. Finally, ValuEngine upgraded OraSure Technologies from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $7.00.

Shares of NASDAQ:OSUR opened at $8.48 on Friday. The company has a current ratio of 6.99, a quick ratio of 6.13 and a debt-to-equity ratio of 0.01. The stock’s fifty day simple moving average is $7.41 and its two-hundred day simple moving average is $8.43. OraSure Technologies has a 1-year low of $6.35 and a 1-year high of $15.11. The stock has a market cap of $523.43 million, a PE ratio of 16.95, a price-to-earnings-growth ratio of 3.23 and a beta of 1.25.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.04. OraSure Technologies had a return on equity of 7.81% and a net margin of 11.83%. The business had revenue of $38.83 million for the quarter, compared to analysts’ expectations of $41.48 million. During the same period last year, the business earned $0.07 EPS. The business’s revenue was down 11.0% on a year-over-year basis. On average, sell-side analysts forecast that OraSure Technologies will post 0.21 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capital Fund Management S.A. bought a new stake in shares of OraSure Technologies during the 2nd quarter worth $160,000. Marshall Wace North America L.P. bought a new stake in shares of OraSure Technologies during the 2nd quarter worth $147,000. Pacer Advisors Inc. bought a new stake in shares of OraSure Technologies during the 2nd quarter worth $104,000. Bank of New York Mellon Corp raised its stake in shares of OraSure Technologies by 4.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 806,976 shares of the medical instruments supplier’s stock worth $7,489,000 after purchasing an additional 37,118 shares during the period. Finally, Bogle Investment Management L P DE raised its stake in shares of OraSure Technologies by 19.5% during the 2nd quarter. Bogle Investment Management L P DE now owns 318,076 shares of the medical instruments supplier’s stock worth $2,952,000 after purchasing an additional 51,913 shares during the period. Institutional investors own 94.52% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Article: What is the price-sales ratio?

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.